These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9100248)

  • 1. Newer therapies for Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Neurol Neurochir Pol; 1996; 30 Suppl 2():105-11. PubMed ID: 9100248
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 3. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 6. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroprotection in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Lancet; 1996 Jan; 347(8995):196. PubMed ID: 8544568
    [No Abstract]   [Full Text] [Related]  

  • 8. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of Parkinson disease. Continuous physiologic dopaminergic stimulation with carbergoline].
    Nervenarzt; 1997 Mar; 68(3 Suppl Therapie D):1-4. PubMed ID: 9404531
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 12. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine".
    Lang AE
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):474-82. PubMed ID: 3315148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleep attacks in Parkinson's disease.
    Pirker W; Happe S
    Lancet; 2000 Aug; 356(9229):597-8. PubMed ID: 10950264
    [No Abstract]   [Full Text] [Related]  

  • 15. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 17. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.
    Blanchet PJ
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S21-6. PubMed ID: 10451756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonists and Parkinson's disease.
    Burton K; Calne DB
    Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New dopamine agonists on the horizon.
    Heins JR
    S D J Med; 1997 Jul; 50(7):239-40. PubMed ID: 9240032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.